Oxidative lipid, protein, and DNA damage as oxidative stress markers in vascular complications of diabetes mellitus

Clinical and Investigative Medicine

Volumn 34, Issue 3, 2011, Pages

  Tabak, Omur ^a   Gelisgen, Remise ^b   Erman, Hayriye ^b   Erdenen, Fusun ^a   Muderrisoglu, Cüneyt ^a   Aral, Hale ^a   Uzun, Hafize ^b  

^a Istanbul Education and Research Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

15 F2T ISOPROSTANE; 15-F2T-ISOPROSTANE; 8 HYDROXYDEOXYGUANOSINE; 8-HYDROXY-2'-DEOXYGUANOSINE; ARYLDIALKYLPHOSPHATASE; DEOXYGUANOSINE; DRUG DERIVATIVE; ISOPROSTANE DERIVATIVE; PON1 PROTEIN, HUMAN; PROTEIN;

ARTICLE; BLOOD; DIABETES MELLITUS; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARYLDIALKYLPHOSPHATASE; DEOXYGUANOSINE; DIABETES MELLITUS; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ISOPROSTANES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROTEINS;

EID: 80051777094     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38.
2. ε-(hexanonyl)lysine in protein exposed to lipid hydroperoxide. A plausible marker for lipid hydroperoxidederived protein modification. J Biol Chem 1999; 274:20406-14.
3. ε-(Hexanoyl)lysine in human urine by liquid chromatography/tandem mass spectrometry. Free Radic Biol Med 2004;37:1864-74.
4. Tomaru M, Takano H, Inoue K, Yanagisawa R, Osakabe N, Yasuda A et al. Pulmonary exposure to diesel exhaust particles enhances fatty change of the liver in obese diabetic mice. Int J Mol Med 2007;19:17-22.
5. Woods AA, Linton SM, Davies MJ. Detection of HOCl mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem J 2003;370:729-35.
6. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221-25.
7. Skvarilová M, Bulava A, Stejskal D, Adamovská S, Bartek J. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005;149:83-7.
8. Cakatay U. Protein oxidation parameters in type 2 diabetic patients with good and poor glycaemic control. Diabetes Metab 2005;31:551-57.
9. Kalousová M, Zima T, Tesar V, Dusilová-Sulková S, Skrha J. Advanced glycoxidation end products in chronic diseasesclinical chemistry and genetic background. Mutat Res 2005;579:37-46.
10. Nishikawa T, Sasahara T, Kiritoshi S, Sonoda K, Senokuchi T, Matsuo T et al. Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003;26:1507-12.
11. Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S et al. Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes 2005;54:727-35.
12. Kakimoto M, Inoguchi T, Sonta T, Yu HY, Imamura M, Etoh T et al. Accumulation of 8-Hydroxy-2'-Deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes 2002;51:1588-95.
13. Kanauchi M, Nishioka H, Hashimoto T. Oxidative DNA damage and tubulointerstitial injury in diabetic nephropathy. Nephron 2002;91:327-29.
14. Taber DF, Morrow JD, Roberts LJ 2nd. A nomenclature system for the isoprostanes. Prostaglandins Other Lipid Mediat 2004;73:47-50.
15. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002;23:360-6.
16. Davì G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004;128:149-63.
17. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005;69:541-50.
18. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM. et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
19. Gugliucci A, Lunceford N, Kinugasa E, Ogata H, Schulze J, Kimura S. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients. Clin Chim Acta 2007;384:105-12.
20. Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T et al. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 2006;185:191-200.
21. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
22. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008;8:51-7.
23. Johansen JS, Harris AK, Rychly DJ, Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005;4(1):5.
24. Davì G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S et al. In vivo formation of 8-iso prostaglandin F2 alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99:224-29.
25. Roberts LJ, Morrow JD. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-13.
26. Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004;38:105-22.
27. Davi{dotless}' G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. Antioxid Redox Signal 2005;7:256-68.
28. Calabrese V, Mancuso C, Sapienza M, Puleo E, Calafato S, Cornelius C et al. Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones 2007;12:299-306.
29. Cristina Polidori M, Pratico D, Savino K, Rokach J, Stahl W, Mecocci P. Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. J Card Fail 2004;10:334-38.
30. Memisogullari{dotless} R, Taysi{dotless} S, Bakan E, Capaoglu I. Antioxidant status and lipid peroxidation in type 2 diabetes mellitus. Cell Biochem Funct 2003;21:291-96.
31. Kajanachumpol S, Komindr S, Mahaisiriyodom A. Plasma lipid peroxide and antioxidant levels in diabetic patients. J Med Assoc Thai 1997;80:372-7.
32. Tomaru M, Takano H, Inoue K, Yanagisawa R, Osakabe N, Yasuda A et al. Pulmonary exposure to diesel exhaust particles enhances fatty change of the liver in obese diabetic mice. Int J Mol Med 2007;19:17-22.
33. Gopaul NK, Anggård EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-29.
34. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovascular Research 2000;47:475-88.
35. Huang HY, Helzlsouer KJ, Appel LJ. The effects of vitamin C and vitamin E on oxidative DNA damage: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2000;9:647-52.
36. Suzuki S, Hinokio Y, Komatu K, Ohtomo M, Onoda M, Hirai S. et al. Oxidative damage to mitochondrial DNA and its relationship to diabetic complications. Diabetes Res Clin Pract 1999;45:161-68.
37. Pan HZ, Chang D, Feng LG, Xu FJ, Kuang HY, Lu MJ. Oxidative damage to DNA and its relationship with diabetic complications. Biomed Environ Sci 2007;20:160-3.
38. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
39. Pan HZ, Zhang H, Chang D, Li H, Sui H. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br J Ophthalmol 2008;92:548-51.
40. Kalousová M, Skrha J, Zima T. Advanced glycation endproducts and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597-604.
41. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.
42. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus Diabetes Research and Clinical Practice 2007;77:188-92.
43. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-54.
44. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35.
45. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B et al. Serum paraoxonase PON1 55 and 192 polymorphism and paraoxonase activity and concentration in non insulin dependent diabetes mellitus. Atherosclerosis 1998;139:341-49.
46. Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI. Low paraoxonase activity in type 2 diabetes mellitus complicated by retinopathy. Clin Science 2000;98:355-63.
47. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 2004;22:163-68.
48. Poh R, Muniandy S. Paraoxonase 1 activity as a predictor of cardiovascular disease in type 2 diabetes. Southeast Asian J Trop Med Public Health 2010;41:1231-46.
49. Jornayvaz FR, Brulhart-Meynet MC, James RW. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009;19:613-9.